Integrating nutrition and proteomics to improve chemotherapy-induced peripheral neuropathy in cancer survivors
Active Grant Awarded
- Award ID
- K99CA308896
- Recipient
-
Adventist Health System / Sunbelt Inc. UEI K3YFW6S3YQ67
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $176,256
Award facts
- Assistance listing
- 93.398 Cancer Research Manpower
- Completion date 27% complete
- Place of performance
- Baton Rouge, LA 70808, USA
Award details come from USAspending.gov.
About this award
The National Cancer Institute, within the Department of Health and Human Services' National Institutes of Health, awarded Adventist Health System / Sunbelt Inc., doing business as Adventhealth Orlando, $176,256 under Grant K99CA308896 on May 7, 2026, through the Cancer Research Manpower program (CFDA 93.398). The award funds research on integrating nutrition and proteomics to address chemotherapy-induced peripheral neuropathy (CIPN) in cancer survivors receiving platinum-based chemotherapy. Under Aim 1, the recipient will determine the relationship between diet and CIPN incidence across multiple cancer types, leveraging the NCI-sponsored Exercise and Nutrition Interventions to Improve Cancer Treatment-Related Outcomes (ENICTO) consortium. The project also aims to create a testable assay of CIPN mechanisms, building on the hypothesis that diet reduces inflammation and oxidative stress as reflected in the proteome. The period of performance runs through April 30, 2028, with place of performance in Baton Rouge, Louisiana 70808.
Description
- Abstract
- Platinum-based chemotherapy is the standard of care for several cancers; however, chemotherapy-induced peripheral neuropathy (CIPN) results in lower quality of life and chemotherapy dose reductions that reduce survival. Platinum-based chemotherapies induce DNA damage to neuronal cells. Increases in pro-inflammatory cytokines interleukin (IL)-1Β, IL-6, and tumor necrosis factor alpha (TNF-Α), decreases in anti-inflammatory cytokines (IL-10, IL-4), and increased oxidative stress alters neuronal excitability, resulting in tingling, pain, and changes to physical function associated with CIPN. DNA damage also impacts proteins released from cells and downstream cellular regulation reflected in the proteome, representing an opportunity to identify biological mechanisms of CIPN. We have shown that higher dietary quality is associated with reduced incidence of CIPN. However, the pathways to prevention (P2P) workshop, CO-sponsored by five institutes and offices of the national institutes of health, identified a lack of high-quality data on whole diet interventions to manage chemotherapy side effects across cancer types. Characterizing the association between diet and CIPN across multiple cancers, while leveraging methods that capture mechanisms that mediate this relationship, will facilitate clinical nutrition guidelines to improve chemotherapy tolerability and survival. Our overall hypothesis is that diet may impact the development of CIPN by reducing inflammation and oxidative stress as reflected in the proteome in patients receiving platinum-based chemotherapies. Leveraging the NCI-sponsored exercise and nutrition interventions to improve cancer treatment-related outcomes (ENICTO) consortium, we will determine the relationship between diet and CIPN incidence across multiple cancer types (aim 1) and create a testable assay of CIPN mechanisms using proteomics (aim 2). Completion of these aims will inform the conduct of a randomized trial using a dietary intervention to delay CIPN, improve inflammation and antioxidant biomarkers, and prevent reductions in physical functioning (aim 3). This is coupled with a robust career development plan that incorporates didactic coursework, hands-on application, and benchmarks for success to provide the applicant with (1) knowledge in oncology practice and standard of care treatment, (2) expertise in conducting rigorous nutrition interventions in oncology, (3) integration and interpretation of omics and high- throughput data into behavioral clinical trials, and (4) scientific leadership, team management, and mentorship skills to become a successful independent investigator. Combined with a world-class mentoring team and strong institutional support at pennington biomedical research center, this pathway to independence award provides specialized training that optimally positions the applicant towards her career goal of transforming nutrition care in oncology. This research answers the call to action put forth by the P2P workshop and advances research priority missions of the NCI for cancer survivorship and cancer control.
Quick answers
Who received award K99CA308896?
K99CA308896 was awarded to Adventist Health System / Sunbelt Inc. by National Cancer Institute (National Institutes of Health) on May 7, 2026.
How much is award K99CA308896 worth?
$176,256 has been obligated on K99CA308896.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award